uniQure (QURE)
(Delayed Data from NSDQ)
$5.65 USD
+1.09 (23.90%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $5.66 +0.01 (0.18%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.65 USD
+1.09 (23.90%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $5.66 +0.01 (0.18%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
Solid (SLDB) Surges as FDA Lifts Clinical Hold on DMD Drug
by Zacks Equity Research
Solid Biosciences' (SLDB) shares gained significantly after the FDA lifted the clinical hold on its phase I/II trial for its lead candidate, SGT-001 for DMD.
Novartis Announces Positive Data on CAR-T Therapy, Kymriah
by Zacks Equity Research
Novartis (NVS) announces positive results on Kymriah from the JULIET TRIAL in patients with relapsed or refractory diffuse large B-cell lymphoma.
Axovant (AXON) Gains on Licensing Deal with Oxford BioMedica
by Zacks Equity Research
Axovant Sciences' (AXON) shares rally, following news of a licensing deal for AXO-LentiPD from Oxford BioMedica for Parkinson's disease.
Why UniQure (QURE) Stock is Skyrocketing Today
by Madeleine Johnson
On Thursday, shares of leading gene therapy company uniQure (QURE) are skyrocketing, up over 50% in morning trading after it announced that it will launch a pivotal study next year testing AMT-061, the company's promising gene therapy candidate to treat patients with hemophilia B.
uniQure (QURE) in Focus: Stock Moves 11.9% Higher
by Zacks Equity Research
uniQure (QURE) saw its shares rise nearly 12% on the day.
uniQure N.V. (QURE) Shows Strength: Stock Moves 9.1% Higher
by Zacks Equity Research
uniQure N.V. (QURE) was a big mover last session, as the company saw its shares rise a little above 9% on the day.
5 Drug Stocks That Could Be Big Winners this Earnings Season
by Arpita Dutt
Here is a look at five companies including Pfizer (PFE) that sport a favorable Zacks Rank and have a positive earnings ESP.
Can The Uptrend Continue for uniQure N.V. (QURE)?
by Zacks Equity Research
Investors certainly have to be happy with uniQure N.V. (QURE) and its short term performance
Will Uniqure (QURE) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Uniqure NV (QURE).
uniQure (QURE): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
uniQure (QURE) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.